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Abstract
Introduction: Currently fetal nuchal translucency (NT) ≥3.5 mm is an indication for 
invasive testing often followed by chromosomal microarray. The aim of this study was 
to assess the risks for chromosomal aberrations in fetuses with an NT 3.0-3.4 mm, 
to determine whether invasive prenatal testing would be relevant in these cases and 
to assess the residual risks in fetuses with normal non-invasive prenatal test (NIPT) 
results.
Material and methods: A retrospective study and meta-analysis of literature cases 
with NT between 3.0 and 3.4 mm and 2 cohorts of pregnant women referred for 
invasive testing and chromosomal microarray was performed: Rotterdam region (with 
a risk >1:200 and NT between 3.0 and 3.4 mm) tested in the period July 2012 to 
June 2019 and Central Denmark region (with a risk >1:300 and NT between 3.0 and 
3.4 mm) tested between September 2015 and December 2018.
Results: A total of 522 fetuses were referred for invasive testing and chromosomal 
microarray. Meta-analysis indicated that in 1:7.4 (13.5% [95% CI 8.2%-21.5%]) fe-
tuses a chromosomal aberration was diagnosed. Of these aberrant cases, 47/68 (69%) 
involved trisomy 21, 18, and 13 and would potentially be detected by all NIPT ap-
proaches. The residual risk for missing a (sub)microscopic chromosome aberration de-
pends on the NIPT approach and is highest if NIPT was performed only for common 
trisomies–1:21 (4.8% [95% CI 3.2%-7.3%]). However, it may be substantially lowered 
if a genome-wide 10-Mb resolution NIPT test was offered (~1:464).
Conclusions: Based on these data, we suggest that the NT cut-off for invasive testing 
could be 3.0 mm (instead of 3.5 mm) because of the high risk of 1:7.4 for a chromo-
somal aberration. If women were offered NIPT first, there would be a significant di-
agnostic delay because all abnormal NIPT results need to be confirmed by diagnostic 
testing. If the woman had already received a normal NIPT result, the residual risk of 
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1  | INTRODUC TION
Nuchal translucency (NT) ≥3.5 mm (>p99) is a well-recognized 
indication for invasive testing as it is a well-studied ultrasound 
marker for common and uncommon aneuploidies as well as for a 
wide variety of genetic syndromes and structural anomalies.1-6 
Although Kagan et al have previously shown that fetuses with 
NT of 95th centile ≥3.4 mm have a high risk for chromosomal 
aberrations (1:14),7 only a few groups performed chromosomal 
microarray (CMA) analysis in fetuses with NT ≥3.0 mm.8-11 An 
enlarged (apparently isolated) NT of 3.0-3.4 mm is diagnosed 
in about 0.8% of pregnant women undergoing first-trimester 
combined test (CT) and in the absence of the risk assessment 
routinely performed after CT, it might be difficult to counsel 
women and advise an appropriate follow-up test (data from 
71 016 women in Central Region Denmark who had CT in 91 430 
pregnancies with estimated date of delivery 2013-2018. Annual 
report, Danish Fetal Medicine Database 2018; RKKP, Petersen, 
OB [in press]). Neither in the Netherlands nor in Denmark an 
apparently isolated NT of 3.0-3.4 mm alone is an indication for 
invasive testing, although NT measurements are known to be a 
good marker for common aneuploidies.1-3 Cell-free DNA testing 
(so-called non-invasive prenatal test [NIPT]) is currently avail-
able in many countries. It can be offered as part of a contingent 
screening program: after a CT resulting in an increased risk for 
trisomy 13, 18, or 2112-14 or as a first-tier screening test to all 
pregnant women.15 Currently, in some countries a substantial 
number of pregnant women have already had a (targeted) NIPT 
before a 13-week ultrasound scan, whereas others may have a 
choice between NIPT and invasive testing after CT or 13-week 
ultrasound scan without the risk calculation. Whereas the pres-
ence of a structural anomaly or an NT ≥3.5 mm is an internation-
ally recognized indication for invasive testing, the decisions in 
pregnancies with NT slightly lower than 3.5 mm can be difficult.
The aim of this study was to assess the risks for chromo-
somal aberrations in fetuses with an NT 3.0-3.4 mm, to determine 
whether it would be reasonable to offer invasive prenatal testing, 
and to assess the residual risks for (sub)microscopic chromosomal 
aberrations other than trisomy 13, 18, and 21 in fetuses with an NT 
3.0-3.4 mm.
2  | MATERIAL AND METHODS
2.1 | Literature data
To assemble a cohort that was as large as possible, a semi-system-
atic literature search was performed (see Supplementary material, 
Appendix S1). Papers were screened for cohorts of fetuses with NT 
3.0-3.4 mm tested with CMA. Only papers presenting the total num-
ber of fetuses with NT 3.0-3.4 mm and at least the number of abnor-
mal cases among these fetuses were selected. Unfortunately, not all 
publications specified the chromosomal aberrations, and many were 
excluded because the total number of fetuses with NT of interest 
was not specified. Eventually, only 3 publications were selected,9-11 
which provided data on 311 fetuses (Tables 1 and 2).
2.2 | Aarhus cohort
In all, 128 women carrying a fetus with an NT 3.0-3.4 mm at the 
CT were prospectively referred for Agilent genotyping array as 
described before.16 As the formal indication for invasive testing 
is a risk for trisomy 21 >1:300 after CT (or >1:150 for trisomy 13 
and trisomy 18, or single criteria: maternal age >45 years, β human 
chorionic gonadotropin or pregnancy-associated plasma protein A 
<0.2 multiples of the median [MoM] or β human chorionic gon-
adotropin > 5 MoM or NT ≥3.5 mm), not all fetuses with an NT 
3.0-3.4 mm had formal indication for invasive testing. Samples 
were collected between 1 September 2015 until 31 December 
2018 in either of four clinics performing invasive testing in the 
was supported by the Novo Nordisk 
Foundation NNF16OC0018772, and 
Olav Bjørn Petersen was supported by 
the Novo Nordisk Foundation grant 
NNFSA170030576.
1:21 to 1:464 for chromosome aberrations other than common trisomies, dependent 
on the NIPT approach, should be raised. If a pregnant woman declines invasive test-
ing, but still wants a test with a broader coverage of clinically significant conditions 
then the genome-wide >10-Mb resolution NIPT test, which detects most aberrations, 
could be proposed.
K E Y W O R D S
microarray, microdeletion, non-invasive prenatal test, nuchal translucency, prenatal diagnosis, 
submicroscopic chromosomal abnormalities
Key message
The risk for chromosomal aberrations in fetuses with 
nuchal translucency 3.0-3.4 mm is 1:7.4, the risk after nor-
mal NIPT for common trisomies is 1:21, therefore offer-
ing an invasive test with chromosomal microarray could be 
considered. The 10-Mb genome-wide NIPT test offers the 
second highest detection rate.
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Central Denmark Region of 1.2 million inhabitants. Samples rou-
tinely referred for CMA testing with risk <1:300 and NT between 
3 and 3.4 mm were included in this cohort. All cytogenetic tests 
were performed in one central laboratory. To create a homoge-
neous cohort, we excluded cases with hydrops fetalis, hygroma 
colli and other co-existing congenital anomalies evident on the 
dating- or/and the NT scan. Samples were tested with SurePrint 
G3 Human CGH microarray 180K (Agilent Technologies) with 
analysis resolution of c.50 kb as described before.16 The data are 
presented in Tables 1 and 2.
2.3 | Rotterdam cohort
Eighty-three women carrying a fetus with an NT 3.0-3.4 mm at 
the CT were prospectively referred for Illumina single nucleotide 
TA B L E  2   Chromosomal aberrations found in the currently presented cohorts and in the literature
Cohort source n T21 T18 T13
X/Y 
abnormalities Other microscopically detectable Submicroscopic
Grossman 
et al 2019
4/31 4 (not specified) 0
Maya 
et al 2017
11/170 6 1 – trisomy Xa  1
1. 7p mosaic duplication (52 Mb) arr 
7p(0-52,007,108)x2~3
3 (all susceptibility CNV)
1. 16p11.2 duplication (0.7 Mb) 
arr[GRCh37] 16p11.2(29,631,159-
30,281,111)x3
2. 16p11.2 deletion (0.6 MB) 
arr[GRCh37] 16p11.2(29,649,915-
30,281,111)x1
3. 8p23.1 duplication (3.8 MB) 
arr[GRCh37] 8p23.1(8,094,406-
11,898,209)x3
Zhao 
et al 2019
18/110 5 3 3 4 (not specified) 3 (all susceptibility CNV)
1. 22q11 duplication 
(2.8 Mb) arr[GRCh37] 
22q11.21(18,648,855-
21,461,017)x3
2. 16p12.2 deletion (0.7 Mb) 
arr[GRCh37] 16p12.2(21,740,199-
22,442,007)x1
3. 16p12.2 deletion (0.7 Mb) 
arr[GRCh37] 16p12.2(21,740,199-
22,442,007)x1
Current data 
Aarhus (DK)
14/128 8 1 0 2
1. X0/delXq
2. X0 and 
pathogenic 
mos dupl 
12q24 
(13 Mb)
2
1. duplication in 21q "Down Syndrome 
Critical Region" (12.2 Mb)
2. mos 10p deletion arr[GRCh37] 
10p15.3q11.22(136361-46169876)
x2~3
1 syndromic
1. 595kb Xq23 deletion arr[GRCh37] 
Xq23(114242518-114837553)x0 
mat (OMIM 300910)
Current data 
Rotterdam 
(NL)
21/83 13 2 2 0 1
1. 5p15.33p14.3 deletion (19.8 Mb) 
(Cri du Chat syndrome) 
and 5p14.3p11 duplication 
(26.2 Mb) arr[GRCh37] 
5p15.33p14.3(25,328-19,880,618)
x1 dn, 
5p14.3p11(19,892,934-46,138,457)
x3
3 (all susceptibility CNV)
1. 3q29 deletion arr[GRCh37] 
3q29(195,738,406-197,346,566)
x1 dn
2. 16p11.2 deletion and 22q11 
duplication arr[GRCh37] 
16p11.2(29595483_30198151)
x1 dn, 
22q11.21(18844632_21463730)
x3 pat
3. 1q21.1 deletion arr[GRCh37] 
1q21.1(146,493,143-147,858,570)
x1
Total 68 47 11 10
Abbreviation: n, number of abnormal cases/total number tested.
aTrisomy X case is not excluded, because the paper does not describe possible mosaicism in other tissues and so clinical relevancy of this finding 
cannot be excluded. Excluding this case would not notably change the statistical calculations. 
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polymorphism (SNP) genotyping array as described before.17 As the 
formal indication for invasive testing is a risk ≥1:200 based on CT, 
only fetuses with higher post-test risk were offered invasive testing. 
Samples collected in our central location (Erasmus MC) and three 
collaborating hospitals between 1 July 2012 until 30 June 2019 and 
routinely referred for SNP array testing (0.5 Mb resolution) were in-
cluded in this cohort. Only women from the Rotterdam region were 
routinely offered CMA if undergoing an invasive procedure for an in-
creased CT risk and NT <3.5 mm in the Netherlands. All cytogenetic 
tests were performed in one central laboratory. This cohort overlaps 
slightly with the cohort published before.17 To create a homogene-
ous cohort, we excluded cases with hydrops fetalis, hygroma colli, 
and other co-existing congenital anomalies evident on the dating or 
the NT scan. All samples were tested with quantitative fluorescence 
PCR or multiplex ligation-dependent probe amplification to detect 
common aneuploidies (rapid aneuploidy detection). When rapid test 
detected trisomy 21 or 13, such samples were karyotyped to as-
sess the recurrence risk. Cases of triploidy or trisomy 18 were not 
further tested with CMA or karyotyped. All cases showing normal 
rapid aneuploidy detection results or sex-chromosomal aneuploidy 
were tested with Illumina SNP array (Illumina) (HumanCytoSNP-12, 
Infinium_CytoSNP_850K or GSA+MD-24 v1.0 BeadChip, with analy-
sis resolution of c.0.5 Mb) as described previously.18 The data are 
presented in Tables 1 and 2.
Furthermore, we evaluated which aberrations would theoretically 
be missed by current NIPT approaches because of the aberration size 
or not being in the scope of a targeted test (NIPT tests were not per-
formed in this cohort). Detection rates in all groups independent of 
aberration were assumed to be 100% for simplicity. Cytogenomic re-
sults in all cohorts were grouped into several categories depending on 
NIPT strategies that would potentially detect them:
1. Aberrations detectable by targeted NIPT: trisomy 13, 18, and 
21
2. Aberrations detectable by targeted NIPT: trisomy 13, 18, 21, and 
X/Y aneuploidy
3. Aberrations detectable by genome-wide NIPT (autosomal 
>20 Mb)—current Dutch NIPT policy: trisomy 13, trisomy 18, 
trisomy 21, and additional findings: large chromosomal aberra-
tions (aberrations >20 Mb)
4. Aberrations detectable by genome-wide NIPT (>10 Mb), including 
X/Y
5. Submicroscopic aberrations (<10 Mb) not detectable by routine 
genome-wide NIPT strategies mentioned above.
For the purpose of this paper, we assumed that all aneuploidies 
would be detectable by NIPT as well as structural unbalanced aber-
rations larger than the resolution of the particular NIPT approach. 
Unfortunately, it is difficult to assess how many of these cases would 
be missed because of mosaicism and their absence in the cytotro-
phoblast. We did not correct the residual risks for common trisomies 
as presented before.19 The residual risk assessment for common tri-
somies and the positive and negative predicted values in high-risk 
pregnancies that has been reviewed by several authors20-22 and 
therefore this issue was not within the scope of this study.
The focus of this study is the residual risk for chromosomal 
aberrations other than trisomy 13, 18, and 21 in fetuses with NT 
3.0-3.4 mm.
Pooled prevalence (event rates) including 95% CIs were calcu-
lated using a random-effects model23 in Comprehensive meta-analysis 
software version 2 (Biostat Inc.) that employs standard continuity 
corrections for zero-events cells.
2.4 | Susceptibility copy number variants for 
neurodevelopmental disorders
A particular group of submicroscopic aberrations are susceptibility 
copy number variants (CNVs) for (mainly) neurodevelopmental dis-
orders. These are variants of extreme phenotypic heterogeneity and 
of variable expressivity (in contrast to syndromic disorders where 
[a set of] specific features are associated with a particular disease/
syndrome). The expressed phenotypes of these disorders probably 
(partly) depend on the presence of a second-site variant or individ-
ual genetic background. If a susceptibility CNV is found prenatally, 
the risk for developing the disease is still unquantified, as data on 
F I G U R E  1   Forest plot showing event rate of aberrant cases based on cytogenomic results in fetuses with nuchal translucency 3.0-
3.4 mm in selected sources representing the risk for overall risk for chromosomal aberrations in the combined cohort (13.5%, 95% CI 
8.2%-21.5% equivalent to a risk of 1:7.4). Only the first author is given for each study. Boxes represent event rate per source and their size 
is proportional to their weight in the analysis, and lines represent 95% CI. Diamond represents pooled estimate and its width represents the 
95% CI
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individuals with neurodevelopmental phenotypes are mostly post-
natally ascertained.24-26
To our knowledge, there is no study that showed any biologi-
cal mechanisms for the relation between susceptibility CNVs and an 
enlarged NT. It is not yet known whether an enlarged NT should be 
recognized as a second hit in the presence of such a susceptibility 
CNV.27 At this moment finding additional predisposition factors may 
play a role in decision-making in pregnancy; however, it is less likely 
that one would choose invasive testing with a primary aim to investi-
gate susceptibility CNVs. Because reporting susceptibility CNVs can 
be problematic in some clinical settings, we provided risk figures for 
both scenarios, depending on the decisions on reporting susceptibil-
ity CNVs. Discussing the issues of reporting susceptibility CNVs is 
not in the scope of the current paper.
2.5 | Ethical approval
According to the Research Codes of Erasmus MC, data that cannot 
be traced to an individual may be used for research. Patients are 
informed that we may investigate/publish their medical data as long 
as all data remain anonymous and cannot lead to the identification 
of the individual. All presented data were obtained during routine 
diagnostic procedures. All presented data are anonymous and do not 
allow identification of the individual patients.
3  | RESULTS
A total of 522 fetuses with NT 3.0-3.4 mm were subjected to CMA 
testing as the result of an increased risk after CT/enlarged NT 
(Tables 1 and 2). The estimated proportions (event rates) and 95% CI 
of abnormal cases in the selected papers and cohorts, including the 
pooled estimate based on the random-effects model, are shown in 
Figure 1. Meta-analysis of the whole cohort demonstrated a risk of 
1:7.4 (13.5%, 95% CI, 8.2%-21.5%) for an abnormal result in this co-
hort (Table 1). Over all studies, 47 in a total of 68 aberrations (69.1%) 
were either trisomy 13, 18, and 21. Eleven (11/68, 16.2%) aberra-
tions were either sex-chromosome aberrations (both aneuploidy 
and structural aberrations) or chromosomal imbalances >10 Mb. In 
total, 58/522 (11%) cases would also be detected by karyotyping. 
Submicroscopic aberrations were found in 10 cases (10/68 14.7%). 
Most of them (9/10) were susceptibility CNVs. In 1 case (0.2%) out 
of 464 chromosomally normal fetuses a syndromic disorder caused 
by a submicroscopic aberration was found. Therefore, the preva-
lence of submicroscopic aberrations in karyotypically normal fetuses 
(464 = 522-58) was calculated to be 2.2% (10/464): 1.9% (9/464) for 
susceptibility CNVs and 0.2% (1/464) for syndromic CNVs.
The risk of missing an aberration depends on the NIPT approach 
used, and we have generated four hypothetical NIPT scenarios from 
a targeted trisomy 13, 18, and 21 alone to a genome-wide with a 
resolution of 10 Mb, assuming that these NIPTs had no false-neg-
ative results for common trisomies or segmental aberrations that 
were in the scope of the particular test. Not surprisingly the broader 
the NIPT test the fewer aberrations would be potentially missed 
(Table 1).
The residual risk for a chromosomal aberration other than com-
mon trisomies in a fetus with NT 3.0-3.4 mm and with normal re-
sults for chromosomes 13, 18, and 21 was calculated to be 1:21 (all 
aberrations included, 4.8% [95% CI 3.2%-7.3%]) or 1:33 (excluding 
susceptibility CNVs, 3.0% [95% CI 1.7%-5.2%]).
These residual risks can theoretically be substantially lowered 
by genome-wide analysis and higher resolution NIPT. When the ge-
nome-wide NIPT with the currently available 10-Mb genome-wide 
resolution would be used, the residual risk for other syndromic chro-
mosome aberrations might be equivalent to a population risk for a 
submicroscopic CNV, which was previously estimated to be 1:270 
for early-onset syndromic disorders.28
4  | DISCUSSION
Based on two patient cohorts and a literature review, we aimed to 
assess the risks for chromosomal aberrations in fetuses with an NT 
3.0-3.4 mm, to determine whether offering invasive prenatal test-
ing would be reasonable. Our results showed that 13.5% (95% CI 
8.2%-21.5%) of the fetuses tested with microarray demonstrated 
a chromosomal aberration, suggesting a risk of 1:7.4. Because only 
data from invasively tested fetuses were available (please see sec-
tion Study limitation), and the full characteristics of the presented 
cohorts were not available, we compared our pooled estimations to 
the previously published studies to judge to what extent our data 
are representative. To be able to compare the current data with the 
literature cohort tested with karyotyping, we took only microscopi-
cally visible aberrations into account. Strong association between 
chromosomal aberrations and fetal NT >3 mm was already sug-
gested by Pandya et al.29 When karyotypically visible aberrations 
are taken into account, our pooled cohort showed 11% of abnor-
mal cases, whereas the clinical data of Kagan et al7 showed chro-
mosomal aberrations in 7.1% of fetuses (p95 -> 3.4 mm, 507/7109), 
Äyräs et al30 in 9.6% (p95 -> 3.4 mm, 65/679), Nicolaides et al31 in 
13% (NT = 3 mm 7/52) and Bardi et al32 in 14% (p95-p99, 124/894). 
Although the incidence of chromosome aberrations presented in this 
paper is within the previously published range (7%-14%), one has to 
be aware that the incidence based on fetal invasive testing, such as 
in our study, might represent the upper bound risk estimate, but on 
the other hand, in population-based studies the bias could be caused 
by missing pediatric cases with less pronounced symptoms caused 
by a chromosomal aberration that is not always evident at birth or 
even within the first 3 years.
Our study showed that the incidence of chromosomal aberra-
tions in fetuses with NT 3.0-3.4 mm is higher than 1:10. According 
to the current updated ISUOG consensus statement on cell-free 
DNA aneuploidy testing, in women at very high risk after combined 
screening (>1:10, with no ultrasound anomaly) cell-free DNA testing 
should not replace invasive testing.33
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The secondary aim was to assess the residual risks for (sub)mi-
croscopic chromosomal aberrations other than trisomy 13, 18, and 
21. There are only a few studies on microarray results in fetuses with 
NT >3 mm that show the relation between the specific NT thick-
ness 3.0-3.4 mm and the incidence of chromosomal aberrations. In 
the presented pooled cohort, offering NIPT for trisomy 13, 18, and 
21 only will notably lower the residual risk to 1:21; however, it still 
remains higher than the cut-off for offering invasive testing in the 
authors’ countries (1:200 to 1:300). In our pooled cohort, the preva-
lence of submicroscopic aberrations in karyotypically normal fetuses 
was 2.2% (10/464), which seems to be higher than in fetuses tested 
because of advanced maternal age or maternal anxiety (0.84%, 95% 
CI 0.55%-1.30%)28 suggesting that microarray testing may have an 
additional value in prenatal cytogenetic diagnosis not only in fetuses 
with NT >3.5 mm, but in fetuses with NT >3 mm as well.
Counseling for invasive testing for fetal chromosome aberra-
tions has changed, and varies significantly between counties,34 In 
some countries NIPT became a first-tier population screening test, 
whereas in other countries it is a second-tier test. In our opinion, 
pretest counseling of couples opting for or eligible for invasive pre-
natal testing needs to address both the risk of missing aberrations 
that are in the scope of NIPT and the residual risk for other chro-
mosomal aberrations beyond the technical possibilities of NIPT (the 
scope of this paper). Such a residual risk is not only dependent on the 
NIPT approach providing either screening for common aneuploidies 
or broad screening for unbalanced chromosomal aberrations, but 
depends on the results of the ultrasound anomaly scan and the a pri-
ori risk determined by CT as well. The risk for common aneuploidies 
in a high-risk population can be reduced by an additional screening 
test such as NIPT, but it might still remain high enough to offer diag-
nostic invasive testing.
The current study focused on the intermediate NT measure-
ment results (3.0-3.4 mm) that can cause a clinical challenge both 
in the presence or absence of a normal NIPT result. Based on the 
presented data, we discuss a prenatal strategy in different clinical 
scenarios depending on whether a pregnant woman already had a 
(normal) low-risk NIPT result or faces the choice between invasive 
testing and NIPT. In the majority of the pregnant population, the risk 
of submicroscopic chromosomal aberrations is higher than the risk 
of Down syndrome/common trisomies.28,35 In light of our results, 
and the increasing evidence of a very low risk of procedure-related 
miscarriage after invasive procedures,36 we believe it is time to ex-
pand the information to include the residual risk for all chromosomal 
aberrations, when pregnant women are offered the choice between 
invasive testing or NIPT in the case of NT 3.0-3.4 mm.
4.1 | Fetus with NT 3.0-3.4 mm and no 
NIPT performed
Based on the current data and literature review, we suggest that 
not only an NT ≥3.5 mm, but also an NT ≥3.0 mm could be con-
sidered as an indication for invasive prenatal testing because the 
frequency of chromosome aberrations seems to be very high (in 
the presented cohort 1:7.4 and according to the literature at least 
1:147). Our results support the previous studies of both Khalil 
et al and Maya et al, who suggested that invasive testing should 
be offered in case of a fetal NT ≥3.0 mm.9,37 If NIPT is offered as 
the first test, then these women may experience a longer period 
of anxiety (while waiting for a definitive result) because every ab-
normal NIPT result requires subsequent confirmatory diagnostic 
testing. Moreover, such a delay may result in the need for late ter-
mination in affected cases. Therefore, we suggest offering invasive 
testing to this group to make early diagnosis of clinically important 
chromosomal aberrations a reproductive choice. Our conclusion 
is supported by previously published data, which showed that of-
fering NIPT instead of CMA in high-risk pregnancies (after CT) sig-
nificantly decreases the diagnostic yield.14 Pre-test counseling is 
an essential part of the screening procedure because some of the 
women may prefer NIPT over an invasive procedure even when 
having a high-risk pregnancy. Providing up-to-date, balanced, 
and accurate information early in gestation is crucial to facilitate 
patient-informed decision-making.38 In our opinion, the present 
study supports offering invasive testing as an appropriate choice 
with a high detection rate. As always, NIPT could be an alternative 
to invasive testing, in which case we suggest genome-wide NIPT 
with resolution of >10 Mb could be considered.
4.2 | Fetus with NT 3.0-3.4 mm and normal NIPT 
showing no trisomy 13, 18, and 21
For the purpose of this paper, focusing on aberrations beyond NIPT 
scope, we assumed that all common aneuploidies would be detect-
able by NIPT. However, during post-test counseling on normal NIPT 
results, the negative predictive values of NIPT for trisomies 13, 18, 
and 21 have to be discussed. In fact, the residual risks for a chromo-
some aberration that is dependent on a priori risk should be taken 
into account at the time of pre-test counseling in all scenarios. This 
study shows that even when it is assumed that NIPT did not miss tri-
somy 13, 18, or 21, fetuses with NT 3.0-3.4 mm have a residual risk 
of 1:21 (including susceptibility CNVs)—1:33 (excluding susceptibility 
CNVs)—for a fetal chromosomal aberration other than trisomy 13, 
18, and 21. This justifies offering invasive testing followed by CMA, 
regardless of the local policy on reporting susceptibility CNVs. Our 
results confirmed the previously published data and showed that 
not all chromosome aberrations can be detected by offering NIPT 
to women with a high risk after CT.5,6,14,39,40 It has been previously 
shown that CMA is the recommended method in these women if 
they want to be informed of as many chromosomal aberrations as 
possible.8,14,17 Our data suggest that in fetuses with NT 3.0-3.4 mm 
notable numbers of abnormal cases would be missed by targeted 
NIPT for trisomy 13, 18, and 21 and NT measurement in pregnan-
cies with a normal NIPT result has an additional value in assessing 
the residual risk for another chromosome aberration in the individual 
fetus.
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4.3 | Fetuses with NT 3.0-3.4 mm and normal 
genome-wide NIPT (with ~10 Mb resolution, 
including sex-chromosome aberrations) may have 
a population risk for syndromic submicroscopic 
aberrations
The higher the NIPT resolution the fewer aberrations will be 
missed and the residual risk can be substantially reduced and 
perhaps nearly brought to population risk for submicroscopic 
chromosomal aberrations associated with early-onset syndromic 
disorders (1:27028). Our study did not show an increased fre-
quency of early-onset syndromic disorders in fetuses with NT 
3.0-3.4 mm as was seen in fetuses with NT >3.5 mm by Grande 
et al.8 The submicroscopic aberrations that were found in this co-
hort were mostly susceptibility CNV, and in only one case a syn-
dromic disorder was found (OMIM 300910). However, the overall 
incidence of submicroscopic chromosome aberrations was higher 
than in women tested because of advanced maternal age or ma-
ternal anxiety (0.84%, 95% CI 0.55%-1.30%),28 suggesting that mi-
croarray testing may have an additional value also in fetuses with 
NT 3-3.4 mm. Larger cohorts tested with microarray are needed to 
assess the actual frequency of submicroscopic chromosome aber-
rations in this group.
4.4 | Study limitations
A main limitation of the study is that it only includes CMA data from 
fetuses with an NT 3.0-3.4 mm undergoing invasive testing because 
of an increased risk after CT and not only because of an apparently 
isolated NT of 3.0-3.4 mm. Moreover, the cut-off for invasive test-
ing is different in different countries, so there are differences ob-
served between the cohorts. The Rotterdam cohort selection was 
the most stringent (the highest cut-off risk after CT) (Table 1), which 
is reflected in the highest prevalence of aberrations. On the other 
hand Maya et al, who were interested in submicroscopic findings, 
excluded fetuses with risks >1:380, clearly influencing the preva-
lence of aberrations in their cohort.9 This study is based on retro-
spective data, and corrections for MoM of serum markers, maternal 
age or other demographic factors in the whole studied cohort were 
not possible. For the purpose of this study, this was the best group 
we could select, although we are aware that it is a subgroup of the 
general population who opted for invasive testing and most likely 
represents an upper-bound risk estimate. Data on fetuses that were 
invasively tested should be compared with population studies; how-
ever, without CMA testing in all individuals it is difficult to assess 
the frequency of submicroscopic findings, as these may cause syn-
dromes that are not always obvious at birth and may be missed in 
clinical follow up for years.
Finally, only one fetus showed a syndromic disorder due to a sub-
microscopic microarray finding, which is lower than the frequency in 
general population data (1:270),28 most probably explained by the 
limited size of the presented combined cohort.
In our opinion, larger cohorts with enlarged NT 3.0-3.4 mm irre-
spective of the risk calculation after CT should be analyzed to assess 
the true risks of a pathogenic submicroscopic unbalanced chromo-
some aberration in such cases.
The detection rates of NIPT are simplified theoretical calcula-
tions that assumed that all aneuploidies as well as structural unbal-
anced aberrations larger than the resolution of the particular NIPT 
approach would be detectable. While counseling for NIPT, the whole 
test characteristics need to be taken into account, especially includ-
ing potential confined placental mosaicism cases.
5  | CONCLUSION
As 69% of chromosome aberrations found in fetuses with NT 3.0-
3.4 mm involved trisomy 21, 18, and 13, NIPT seems to be an appro-
priate test in such cases at first sight. However, our study shows that 
the overall risk for a chromosome aberration in these fetuses seems to 
be very high (~1:10). As an aberrant NIPT result requires confirmatory 
studies, performing NIPT would delay a final diagnosis in a notable 
number of women. Our study showed that the residual risk for other 
chromosomal aberrations than common trisomies is high 1:21-1:33. 
Therefore, we advise offering invasive testing independent of the 
NIPT results for common trisomies. Nevertheless, the decision should 
always be made by the patient herself and if a pregnant woman carry-
ing a fetus with NT 3.0-3.4 mm declines an invasive procedure, then 
genome-wide NIPT with a resolution of 10 Mb can be proposed as a 
second-option to assure the highest diagnostic yield.
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